Henlius Reported Financial Results for the First Three Quart

SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Henlius（2696.HK）announced its financial results and business update for the first three quarters of 2023. As of September 30, 2023, Henlius generated a total revenue of RMB3.9278 billion, rising by 84.0% YoY, and a profit totaled RMB407.8 million, attributed to the highly efficient commercial operation and successive growth in core products. Among which, HANQUYOU...

Related Keywords

Songjiang , Jilin , China , Cintas , Bahia , Brazil , Switzerland , Singapore , United Kingdom , Shanghai , Canada , Netherlands , Argentina , Indonesia , India , Australia , Xuhui , United States , Saudi Arabia , Chinese , America , Jason Zhu , Wenjie Zhang , European Society Of Medical Oncology , National Medical Products Administration , European Union , Health Canada , Drug Administration , Executive Director , Chief Executive Officer , Chief Financial Officer , New Drug Submission , New Drug Application , North African , Medical Oncology , Songjiang Second Plant , Xuhui Facility , Songjiang First Plant , Pre License Inspection , Youth Care Inspectorate , Good Manufacturing Practice , Xuhui Plant ,